Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370508 | 0.95 | PABPC1 (0.43) | PABPC1EIF4HCTDSP1ALDH1A1KDM4E | |
| SCHEMBL4266264 | 0.93 | — | — | |
| SCHEMBL28143118 | 0.90 | MEN1 (0.36) | SMN1; SMN2 | |
| SCHEMBL4023086 | 0.90 | MEN1 (0.36) | SMN1; SMN2 | |
| SCHEMBL1992347 | 0.86 | PABPC1 (0.33) | PABPC1EIF4HCTDSP1ALDH1A1KDM4E | |
| SCHEMBL1111608 | 0.86 | HTT (0.34) | PABPC1EIF4HCTDSP1ALDH1A1KDM4E | |
| Sulfuric Acid SCHEMBL12544527 | 0.86 | KDM4E (0.30) | ALDH1A1KDM4EHPGD | |
| SCHEMBL7742084 | 0.86 | KDM4E (0.37) | PABPC1EIF4HCTDSP1ALDH1A1KDM4E | |
| Sulfuric Acid SCHEMBL12544523 | 0.84 | — | — | |
| SCHEMBL34898 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12322554-B1 | Dielectric film with polarizable additive, capacitor and method of manufacture | Ehrenberg Industries Corporation (US) | 2025-06-03 | — | — | US | claimed |
| WO-2023021885-A1 | ELECTROLYTIC SOLUTION FOR CAPACITOR AND CAPACITOR | カーリットホールディングス株式会社 | 2023-02-23 | — | — | WO | claimed |
| WO-2023013368-A1 | METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR | カーリットホールディングス株式会社 | 2023-02-09 | — | — | WO | claimed |
| US-20090118558-A1 | Dehydration Process | BP P.L.C. (GB) | 2009-05-07 | — | — | US | claimed |
| EP-1907341-A1 | DEHYDRATION PROCESS | BP p.l.c. (GB) | 2008-04-09 | — | — | EP | claimed |
| WO-2007012825-A1 | DEHYDRATION PROCESS | BP P.L.C. (GB) | 2007-02-01 | — | — | WO | claimed |
| US-12322554-B1 | Dielectric film with polarizable additive, capacitor and method of manufacture | Ehrenberg Industries Corporation (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250174409-A1 | SOLID ELECTROLYTE CAPACITOR AND METHOD FOR MANUFACTURING SAME | CARLIT CO., LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20240285766-A1 | Liquid Protein Formulations Containing Ionic Liquids | EAGLE BIOLOGICS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11986526-B2 | Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) | EAGLE BIOLOGICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-110559435-B | Liquid protein formulations comprising ionic liquids | 伊戈尔生物药品股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230310294-A1 | COMPOSITION FOR SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBERS, COMPRISING A PARTICULAR HETEROCYCLIC SALT, AND PROCESS USING THIS COMPOSITION | L'OREAL (FR) | 2023-10-05 | — | — | US | disclosed |
| WO-2023171344-A1 | SOLID ELECTROLYTE CAPACITOR AND METHOD FOR MANUFACTURING SAME | カーリットホールディングス株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-20180085463-A1 | Liquid Protein Formulations Containing Ionic Liquids | EAGLE BIOLOGICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9833513-B2 | Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof | EAGLE BIOLOGICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3200804-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Eagle Biologics, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3043774-A2 | LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | Arsia Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2016054259-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Arsia Therapeutics, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015038811-A2 | LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | Arsia Therapeutics, Inc. (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150071922-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285766-A1 | Liquid Protein Formulations Containing Ionic Liquids | IGFBP5, IGFBP1, IGF2BP1 | PABPC1 909/4885EIF4H 444/4885CTDSP1 1905/4885 |
| US-20150071922-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | IGFBP5, IGFBP1, IGF2BP1 | PABPC1 909/4885EIF4H 444/4885CTDSP1 1905/4885 |
| US-20230310294-A1 | COMPOSITION FOR SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBERS, COMPRISING A PARTICULAR HETEROCYCLIC SALT, AND PROCESS USING THIS COMPOSITION | KRT18, KAT2B, SPIN2B | PABPC1 3926/4885EIF4H 4614/4885CTDSP1 4082/4885 |
| US-11986526-B2 | Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) | MLEC, DMPK, CD14 | PABPC1 800/4885EIF4H 100/4885CTDSP1 2788/4885 |
| US-20090118558-A1 | Dehydration Process | ADH1A, ADH1C, ADH5 | PABPC1 4579/4885EIF4H 1539/4885CTDSP1 1227/4885 |
| US-20180085463-A1 | Liquid Protein Formulations Containing Ionic Liquids | IGFBP5, IGFBP1, IGF2BP1 | PABPC1 909/4885EIF4H 444/4885CTDSP1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.